CH439279A - Process for the preparation of bis-hydroxymethylene-pregnane - Google Patents

Process for the preparation of bis-hydroxymethylene-pregnane

Info

Publication number
CH439279A
CH439279A CH194261A CH194261A CH439279A CH 439279 A CH439279 A CH 439279A CH 194261 A CH194261 A CH 194261A CH 194261 A CH194261 A CH 194261A CH 439279 A CH439279 A CH 439279A
Authority
CH
Switzerland
Prior art keywords
bis
pregnane
hydroxymethylene
preparation
hydroxy
Prior art date
Application number
CH194261A
Other languages
French (fr)
Inventor
Bertin Daniel
Fritel Hubert
Original Assignee
Roussel Uclaf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roussel Uclaf filed Critical Roussel Uclaf
Publication of CH439279A publication Critical patent/CH439279A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J9/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37Digestive system
    • A61K35/38Stomach; Intestine; Goblet cells; Oral mucosa; Saliva
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J75/00Processes for the preparation of steroids in general

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Description

       

  <B>Procédé de</B>     préparation   <B>de</B>     bis-hydroxyméthylène-pregnane       Dans le brevet     NA    394186, on a décrit un     procédé    de  préparation du     3a-hydroxy-11-céto-20,20-bis-hydroxy-          m6thylène-5(3-pregnane    qui     consiste        principalement    à       faire        réagir,    selon le     principe        de    la réaction de conden  sation de     Tollens.,

      le formol sur le     20-formyl43a-acétoxy-          11-oxo-5(3-pregnane,    la réaction étant catalysée par un       agent    alcalin.  



  Ce produit se signale par son activité     cardiotropique          accompagnée    d'une     action        dilatatrice        des        coronaires.     Il est donc     utilisable    chaque fois qu'une action spéci  fique sur le muscle cardiaque est nécessaire,

       cette    action       étant    de     surcroît        accompagnée    d'uns     augmentation        b6né-          fique    de     l'irrigation.        sanguine        dudit    muscle cardiaque.  



  Or, on a trouvé     maintenant    qu'un nouveau composé  appartenant au même groupe que le     composé    décrit  dans le brevet No 394186,     ,mais    ayant un hydroxyle au  lieu d'une cétone en     position    11, exerce encore la même  activité.

   Ces composés     peuvent    être     symbolisés    par la       formule    commune suivante  
EMI0001.0041     
    La     présente    invention se rapporte donc à la pré  paration de ce nouveau     composé,    à savoir le 3 a, l l     (3-          dihydroxy-20,20-bis-hyâroxym6thylène-5(3-pregnane,    qui  est obtenu .par la     réduction    du     3a,hydroxy-11-céto-          20,20-bis-hydroxyméthylène-5(3-pregnane    en     3a,11(3-          dihydroxy-20,

  20-bis-hydroxyméthydène-5(3-pregnâne    au  moyen d'un hydrure     mixte    alcalin dans un     milieu          approprié.     



       Dans    un mode d'exécution du     procédé        ci-dessus,    la  réduction est     effectuée    par action de l'hydrure de lithium  et     d'aluminium,        dans    le     tétrahydrofurane,    .mais on peut  également réduire la cétone en 11 par d'autres agents  de     .réduction        stéréospécifiques    tels que les     borohydrures     de potassium, sodium ou     lithium.     



       L'exemple    suivant illustre l'invention.  Exemple  <I>Préparation du</I>     3a,11(3-dihydroxy-20,20-bis-          (hydroxyméthylène)-S(3-preQnane     
EMI0001.0068     
    On introduit dans 30     #n3    de     tétrahydrofurane     800. mg     d'hydrure    de lithium et     d'aluminium    en main  tenant la     température    à     18o    C par un bain d'eau et de  glace.

       Puis,    on ajoute en     quinze        minutes,    à la même       température,    la     solution        suivante     - 50     cm3    de     tétrahydrofurane     - 800 mg de 3a     hydroxy-11-céto-20,20        bis-(hydroxy-          méthylène)-5        p-pregnane.     



  Ensuite, on ajoute     encore    15     cm3    de     tétrahydro-          furane    et     agite    le     mélange        réactionnel    pendant     quatre     heures, à     température    ambiante, et sous azote. L'excès           d'hydrure    de     lithium    et     d'aluminium    est     détruit    par       addition    de 16     cm3        d'acétate    d'éthyle.

   On introduit alors  sous agitation environ 18     cm3    d'une     solution    saturée de       chlorure    de     sodium        diluée    su     demi.    Le     précipité        minéral     formé est séparé e     la,

      phase organique puis     extrait    par  de     l'acétate        d'éthyle.    Les     solutions    organiques jointes  sont     ensuite    lavées par une     solution    saturée de chlorure  de     sodium        diluée    au demi, puis séchées sur sulfate de  sodium et évaporées sous vide.  



  La résine obtenue est dissoute dans 48     cm3    d'éthanol  que     l'on:        filtre,        concentre        ensuite    à 8     cm3    environ et  précipite à chaud par 10=3 d'eau. On essore alors le       précipité,        lave    à     l'alcool    à     50        %        glacé        et        sèche    à     800        C.     



  Les     cristaux    obtenus sont dissous dans un mélange  de toluène et     d'alcool;    la     solution    obtenue concentrée  et le produit cristallisé par     refroidissement.    On     obtient     374. mg, soit un     rendement    de 48 0/0, de produit de       fomnule    I, E = 210o C, [a]= + 35,8o (c = 1D 0/0,  éthanol).  



       Par        récupération    du deuxième jet à partir     des    eaux  mères de     purification:    à     l'alcool,    le rendement peut être       amélioré    de 13 0/0, ce qui donne au total un rendement  de 61 0/0.  



  Le     produit    est     soluble    dans l'alcool, peu soluble  dans le toluène et ]!,acétone,     insoluble    dans l'eau, l'éther,  le     benzène    et le     chloroforme.     



  <I>Analyse :</I>     C,3H4004    = 380,55       Calculé    :     C        72,59        %        H        10,59        %          Trouvé    :     C        72,9        %        H        10,6        %            Ce    composé n'est pas décrit dans la     littérature.     



  Le composé de départ a été     préparé    d'après la  technique     d'écrite        dans    le brevet     .principal    par conden  sation -du formol par     réaction    de     Tollens    sur le     20-for-          myl-3a-acétoxy-11-oxo-5a        pregnane    en présence d'hy  droxyde de potassium.



  <B> Process for </B> preparation <B> of </B> bis-hydroxymethylene-pregnane In patent NA 394186, a process for the preparation of 3a-hydroxy-11-keto-20,20-bis has been described -hydroxy-methylene-5 (3-pregnane which consists mainly in reacting, according to the principle of the Tollens condensation reaction.,

      formalin on 20-formyl43a-acetoxy-11-oxo-5 (3-pregnane, the reaction being catalyzed by an alkaline agent.



  This product is distinguished by its cardiotropic activity accompanied by a dilating action of the coronaries. It can therefore be used whenever a specific action on the heart muscle is necessary,

       this action being moreover accompanied by a beneficial increase in irrigation. blood from said heart muscle.



  However, it has now been found that a new compound belonging to the same group as the compound described in patent No. 394186, but having a hydroxyl instead of a ketone in position 11, still exercises the same activity.

   These compounds can be symbolized by the following common formula
EMI0001.0041
    The present invention therefore relates to the preparation of this new compound, namely 3 a, ll (3-dihydroxy-20,20-bis-hyâroxym6thylène-5 (3-pregnane, which is obtained by the reduction of 3a , hydroxy-11-keto-20,20-bis-hydroxymethylene-5 (3-pregnane in 3a, 11 (3-dihydroxy-20,

  20-bis-hydroxymethydene-5 (3-pregnane by means of a mixed alkali hydride in a suitable medium.



       In one embodiment of the above process, the reduction is carried out by the action of lithium aluminum hydride in tetrahydrofuran, but the 11-ketone can also be reduced by other agents. stereospecific reduction such as potassium, sodium or lithium borohydrides.



       The following example illustrates the invention. Example <I> Preparation of </I> 3a, 11 (3-dihydroxy-20,20-bis- (hydroxymethylene) -S (3-preQnane
EMI0001.0068
    800 mg of lithium aluminum hydride are introduced into 30 # n3 of tetrahydrofuran while maintaining the temperature at 18 ° C. by a water and ice bath.

       Then, the following solution - 50 cm3 of tetrahydrofuran - 800 mg of 3a hydroxy-11-keto-20,20 bis- (hydroxymethylene) -5 p-pregnane is added over fifteen minutes at the same temperature.



  Then, another 15 cm 3 of tetrahydrofuran is added and the reaction mixture is stirred for four hours at room temperature and under nitrogen. The excess of lithium aluminum hydride is destroyed by adding 16 cm3 of ethyl acetate.

   About 18 cm3 of a saturated solution of sodium chloride diluted in half are then introduced with stirring. The mineral precipitate formed is separated from it,

      organic phase then extracted with ethyl acetate. The combined organic solutions are then washed with a saturated solution of sodium chloride diluted to half, then dried over sodium sulfate and evaporated in vacuo.



  The resin obtained is dissolved in 48 cm3 of ethanol which is filtered, then concentrated to approximately 8 cm3 and precipitated hot with 10 = 3 of water. The precipitate is then filtered off, washed with ice-cold 50% alcohol and dried at 800 C.



  The crystals obtained are dissolved in a mixture of toluene and alcohol; the solution obtained concentrated and the product crystallized on cooling. 374 mg, ie a yield of 48 0/0, of product of formula I, E = 210 ° C, [a] = + 35.8 ° (c = 1D 0/0, ethanol) are obtained.



       By recovering the second stream from the mother liquors for purification: with alcohol, the yield can be improved by 13%, which gives a total yield of 61%.



  The product is soluble in alcohol, sparingly soluble in toluene and] !, acetone, insoluble in water, ether, benzene and chloroform.



  <I> Analysis: </I> C, 3H4004 = 380.55 Calculated: C 72.59% H 10.59% Found: C 72.9% H 10.6% This compound is not described in the literature .



  The starting compound was prepared according to the technique described in the main patent by condensation of formalin by the Tollens reaction with 20-formyl-3a-acetoxy-11-oxo-5a pregnane in the presence of potassium hydroxide.


    

Claims (1)

REVENDICATION Procédé de préparation du 3a,11(3-dihydroxy-20,20- bis-hydroxyméthylène^5p- pragnane, caractérisé en ce que l'on réduit le 3a-hydroxy-11-céto-20,20-bis-hydroxy- méthylène-5p- pregnane en 3a,11p-dihydroxy-20,20-bis- hydroxyméthylène-5(3-pregnane au moyen d'un hydrure mixte alcalin dans un milieu approprié. SOUS-REVENDICATIONS 1. CLAIM Process for the preparation of 3a, 11 (3-dihydroxy-20,20- bis-hydroxymethylene ^ 5p-pragnane, characterized in that the 3a-hydroxy-11-keto-20,20-bis-hydroxy- is reduced. methylene-5p-pregnane in 3a, 11p-dihydroxy-20,20-bis-hydroxymethylene-5 (3-pregnane by means of an alkali mixed hydride in a suitable medium. SUB-CLAIMS 1. Procédé suivant la revendication, caractérisé en ce qu'on emploie, connue hydrure mixte alcalin, le borohydrure de métal alcalin, tel que potassium, sodium ou lithium, ou #1'hydrure de lithium et d'aluminium. 2. Procédé suivant la revendication, caractérisé en ce que le milieu ide la réaction est constitué par le tétrahydrofurane. Process according to claim, characterized in that, as known mixed alkali hydride, alkali metal borohydride, such as potassium, sodium or lithium, or lithium aluminum hydride is employed. 2. Method according to claim, characterized in that the medium ide the reaction consists of tetrahydrofuran.
CH194261A 1960-06-20 1961-02-17 Process for the preparation of bis-hydroxymethylene-pregnane CH439279A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR830527A FR83002E (en) 1960-06-20 1960-06-20 Bis-hydroxymethylene pregnane and process for obtaining it

Publications (1)

Publication Number Publication Date
CH439279A true CH439279A (en) 1967-07-15

Family

ID=8733789

Family Applications (1)

Application Number Title Priority Date Filing Date
CH194261A CH439279A (en) 1960-06-20 1961-02-17 Process for the preparation of bis-hydroxymethylene-pregnane

Country Status (3)

Country Link
CH (1) CH439279A (en)
ES (1) ES264426A2 (en)
FR (2) FR83002E (en)

Also Published As

Publication number Publication date
ES264426A2 (en) 1961-07-01
FR83002E (en) 1964-05-29
FR133M (en) 1961-02-06

Similar Documents

Publication Publication Date Title
Schaffer et al. Structure of 5-Aldo-1, 2-O-isopropylidene-D-xylo-pentofuranose1
JPH0211563A (en) Preparation of 1beta-hydroxyvitamin d2 and d3
CH439279A (en) Process for the preparation of bis-hydroxymethylene-pregnane
Geissman et al. Anthochlor pigments. IX. The structure of the aurone pigment of Cosmos sulfureus,“orange flare” and “yellow flare”
EP0071500B1 (en) Process for the preparation of 4-aminobutyramide
CA1072540A (en) Novel 2,2-dimethyl steroids and a process for the preparation thereof
EP0466583B1 (en) Process for the preparation of 2,5-dimethyl-4-hydroxy-3(2H)-furanone
BE818471A (en) PROCESS FOR PREPARING 1-ARALKYL-4-AMINO-METHYLPIPERIDINE-4-OLS
US3647831A (en) Processes for preparing equilenin compounds
BE826668A (en) 3,14-DIHYDROCRIOCERINE AND METHOD OF PREPARATION.
FR2534583A1 (en) Process for the production of hexahydro-5-hydroxy-4-hydroxymethyl-2H-cyclopenta[b]furan-2-one
CH388975A (en) Process for the preparation of a reserpine derivative
CH374066A (en) Process for preparing trisubstituted derivatives of etiocholane
BE569183A (en)
CH340816A (en) Process for the preparation of novel thioderivatives of colchiceines
BE837804A (en) DERIVATIVES OF THIOPHENE OR FURANNE AND PROCESS FOR THEIR PREPARATION
BE826375A (en) NEW CHEMICAL COMPOUNDS FOR THE TREATMENT OF ARTERIOSCLEROSIS, TROMBOSIS, HYPERTENSION AND LIPID METABLISM DISORDERS
CH324533A (en) Process for the preparation of adrenosterone derivatives
BE864336A (en) NEW ANTHRACYCLINE DERIVATIVES
CH364497A (en) Process for the preparation of glycol monoethers
BE826066A (en) NEW TETRAHYDROQUINOLEIN SKELETON DERIVATIVES PREPARED FROM TABERSONIN
CH323174A (en) Process for preparing a steroid carrying an aldehyde function in position 17
BE633627A (en)
CH347523A (en) Process for the preparation of diesters of 9x-halo-16x-hydroxy-hydrocortisones
CH513144A (en) Antiandrogenic and gestagenic a-nor-delta- - 3-progesterones